Total Holdings
23
As of Oct 4, 2026
Amplify Weight Loss Drug & Treatment ETF
THNRNYSEARCAAmplify InvestmentsEquity
$24.51Today:- (-)1Y +5.91%
As of Oct 16, 2026 close
- Assets (AUM)
- $5.64M
- Expense ratio
- 0.59%
- Dividend yield
- 1.67%
- Holdings
- 23
- 52-week range
- $22.89$27.94
- Volume (live)
- -
- Avg. volume (3M)
- 717
THNR ETF Holdings: Amplify Weight Loss Drug & Treatment ETF
Every listed position with its portfolio weight, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Top 10 Holdings
62.4%
Share of fund assets
Assets (AUM)
$5.64M
Total fund assets
Expense Ratio
0.59%
Annual management fee
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
All 25 THNR Holdings by Portfolio Weight
Holdings as of Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position.
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Eli Lilly and Company | Stock | 10.19% |
| 2 |  | Novo Nordisk A/S | Stock | 8.45% |
| 3 | HKG:1093 | CSPC Pharmaceutical Group Limited | Stock | 5.92% |
| 4 |  | Viking Therapeutics Inc | Stock | 5.68% |
| 5 |  | Amgen Inc. | Stock | 5.65% |
| 6 |  | Pfizer Inc. | Stock | 5.40% |
| 7 | HKG:1801 | Innovent Biologics, Inc. | Stock | 5.39% |
| 8 | LSE:AZN | AstraZeneca PLC | Stock | 5.26% |
| 9 | SWX:ROP | Roche Holding AG | Stock | 5.26% |
| 10 | LON:AZN | AstraZeneca PLC | Stock | 5.24% |
| 11 |  | AbbVie Inc | Stock | 5.16% |
| 12 |  | Gilead Sciences, Inc | Stock | 5.13% |
| 13 |  | Regeneron Pharmaceuticals, Inc | Stock | 5.13% |
| 14 |  | Merck & Co., Inc | Stock | 5.08% |
| 15 | TSE:4519 | Chugai Pharmaceutical Co. Ltd. | Stock | 4.96% |
| 16 | TYO:4519 | Chugai Pharmaceutical Co., Ltd. | Stock | 4.55% |
| 17 |  | Arrowhead Pharmaceuticals, Inc. | Stock | 4.04% |
| 18 | CO:ZEAL | Zealand Pharma A/S | Stock | 3.94% |
| 19 | MUTF:AGPXX | Invesco Shrt-Trm Inv Gov&Agcy Instl | Stock | 3.94% |
| 20 | CPH:ZEAL | Zealand Pharma A/S | Stock | 3.74% |
| 21 |  | Structure Therapeutics Inc. American Depositary Shares | Stock | 3.72% |
| 22 | KRX:128940 | Hanmi Pharm. Co., Ltd. | Stock | 3.56% |
| 23 | OTC:JNGHF | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Stock | 2.41% |
| 24 | NMFQS:AGPXX | Short-Term Investment Trust - Invesco Government & Agency Portfolio | Cash | 1.19% |
| 25 |  | Kailera Therapeutics, Inc. Common Stock | Stock | 1.01% |
Source: Fund holdings disclosures. Data as of Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About Amplify Weight Loss Drug & Treatment ETF Holdings
What are the top holdings in THNR?
As of Oct 4, 2026, Amplify Weight Loss Drug & Treatment ETF (THNR) holds 23 securities. The largest are Eli Lilly and Company (10.19%), Novo Nordisk A/S (8.45%), CSPC Pharmaceutical Group Limited (5.92%). The holdings table lists each position by portfolio weight with its ticker, name and asset type.
How concentrated is THNR's portfolio?
As of Oct 4, 2026, the 10 largest positions make up 62.4% of THNR's assets. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly.
What is THNR's sector allocation?
The Sector Allocation chart shows how THNR distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does THNR invest in?
THNR's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is THNR ETF?
THNR's diversification can be assessed by reviewing its 23 holdings (as of Oct 4, 2026), sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.